Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01748149 · ClinicalTrials.gov registry record · Early Phase 1
Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas
A Early Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 40
- Enrollment target
NCT01748149 is a Early Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 40 participants.
The verdict
NCT01748149, a Early Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a multicenter, safety and pharmacokinetic trial to determine the MTD and/or select a recommended phase 2 dose (RP2D) of vemurafenib in children with recurrent or refractory gliomas containing the BRAFV600E or BRAF Ins T mutation.
Interventions
- DRUG Vemurafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2014-04-29 |
| Est. Completion | 2025-07-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01748149
The ClinicalTrials.gov registry entry for NCT01748149 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vemurafenib is the first listed.
NCT01748149 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01748149 about?
NCT01748149 is a clinical study titled "Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas". This is a multicenter, safety and pharmacokinetic trial to determine the MTD and/or select a recommended phase 2 dose (RP2D) of vemurafenib in children with recurrent or refractory gliomas containing the BRAFV600E or BRAF Ins T mutation.
What is the current status of trial NCT01748149?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 40 participants. The study started on 2014-04-29. Estimated completion is 2025-07-31.
What interventions are being tested in trial NCT01748149?
The interventions under investigation include: Vemurafenib (DRUG).
Who is sponsoring clinical trial NCT01748149?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.